Spots Global Cancer Trial Database for Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses

Official Title: Chronic Effect of Doxorubicin and Cyclophosphamide on Neurovascular Control and Blood Pressure in Women in Adjuvant Treatment for Breast Neoplasia

Study ID: NCT04568161

Conditions

Cardiotoxicity

Cardiovascular Disease

Neurovascular Disorder

Endothelial Disfunction

Breast Cancer

Interventions

Physical Characteristics

Muscular Sympathetic Nervous Activity

Endothelium-dependent vascular function

Vascular intima-media thickness

Physical Capacity

Anthracycline & Cyclophosphamide treatment scheme

Study Description

Brief Summary: The present study aims to investigate the chronic effect of treatment with doxorubicin and cyclophosphamide on neurovascular control and blood pressure in women undergoing adjuvant treatment for breast cancer.

Detailed Description: The development of new drugs and different adjuvant therapeutic regimens, based on the combination of anthracycline (A) and cyclophosphamide (C), have contributed greatly to improve survival rate in breast cancer patients. Despite the clinical benefits of this therapy, AC treatment can cause cardiovascular acute and chronic changes. In a recent investigation, we observed that an acute AC chemotherapy session increases sympathetic nervous activity and blood pressure in patients with breast cancer. The present study aims to investigate the chronic effects of AC regimen on sympathetic nervous activity, peripheral vasoconstriction, endothelial microparticles and blood pressure, in women with breast cancer.